Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656692 | 0.86 | MAPT (0.46) | MAP3K14MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL19651541 | 0.86 | MAP3K14 (0.41) | MAP3K14MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17192436 | 0.85 | MAPT (0.51) | MAP3K14MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL15748777 | 0.84 | MAPT (0.56) | MAP3K14MAPT | |
| SCHEMBL15748811 | 0.83 | MAPT (0.55) | MAP3K14MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17192451 | 0.82 | MAP3K14 (0.44) | MAP3K14MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17192447 | 0.82 | MAPT (0.54) | MAP3K14MAPT | |
| SCHEMBL15748815 | 0.81 | MAPT (0.53) | MAP3K14MAPTKDM4E | |
| SCHEMBL15748810 | 0.81 | MAPT (0.53) | MAP3K14MAPTKMT2AKDM4E | |
| SCHEMBL15748852 | 0.81 | MAPT (0.38) | MAP3K14MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| WO-2016086136-A1 | FATTY ACID CYSTEAMINE CONJUGATES OF CFTR MODULATORS AND THEIR USE IN TREATING MEDICAL DISORDERS | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | MAP3K14 3509/4885MAPT 867/4885ALDH1A1 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.